Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant
Study sponsor: Marker Therapeutics, Inc. · MRKR
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-03-01Actual
Enrollment · participants92Actual
Source updated2025-10-30Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.